Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Burcu TepekuleDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.ORCID 0000-0001-6936-9138
Weronika BarcikDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.ORCID 0000-0001-8580-9690
Willy I StaigerDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.ORCID 0009-0007-9869-9292
Judith Bergadà-PijuanDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.
Thomas ScheierDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.
Laura BrülisauerDepartment of Environmental Systems Science, Institute of Integrative Biology, ETH Zurich, Zurich 8092, Switzerland.ORCID 0000-0002-1847-674X
Alex R HallDepartment of Environmental Systems Science, Institute of Integrative Biology, ETH Zurich, Zurich 8092, Switzerland.ORCID 0000-0002-3654-1373
Huldrych F GünthardDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.ORCID 0000-0002-1142-6723
Markus Hilty *Institute for Infectious Diseases, University of Bern, Bern 3001, Switzerland.ORCID 0000-0002-2418-6474
Roger D Kouyos *Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.ORCID 0000-0002-9220-8348
Silvio D Brugger *Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.ORCID 0000-0001-9492-9088
Funding
Gebert Rüf Stiftung (Gebert Rüf Foundation) GRS-09420Promedica Stiftung 1449 MSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) BSSGI0_155851UZH | Foundation for Research in Science and the Humanities (Stiftung für wissenschaftliche Forschung) K-84804 - 01 - 01
6 · The paper itself
Abstract
Despite the rising challenge of antibiotic resistance, current approaches to eradicate nasal pathobionts
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Computational and in vitro evaluation of probiotic treatments for nasal · full record | OpenQuestion